135 related articles for article (PubMed ID: 16457759)
1. [Genotypic hypervariability of melanoma: a therapeutic challenge].
Dalle S; Martin-Denavit T; Thomas L
Med Sci (Paris); 2006 Feb; 22(2):178-82. PubMed ID: 16457759
[TBL] [Abstract][Full Text] [Related]
2. Genetic mutations involved in melanoma: a summary of our current understanding.
High WA; Robinson WA
Adv Dermatol; 2007; 23():61-79. PubMed ID: 18159896
[TBL] [Abstract][Full Text] [Related]
3. [Molecular biology of familial cases of human melanoma].
Kit OI; Vodolazhsky DL; Timoshkina NN; Przhedetsky YV; Khokhlova OV
Vopr Onkol; 2015; 61(6):889-97. PubMed ID: 26995975
[TBL] [Abstract][Full Text] [Related]
4. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
5. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma.
Pho L; Grossman D; Leachman SA
Curr Opin Oncol; 2006 Mar; 18(2):173-9. PubMed ID: 16462187
[TBL] [Abstract][Full Text] [Related]
6. The pathway ahead in melanoma trials.
Miller AJ; Markovic SN; Haluska P
Oncology (Williston Park); 2009 May; 23(6):496, 498, 500. PubMed ID: 19544690
[No Abstract] [Full Text] [Related]
7. Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome.
Celebi JT; Ward KM; Wanner M; Polsky D; Kopf AW
Clin Exp Dermatol; 2005 Jan; 30(1):68-70. PubMed ID: 15663508
[TBL] [Abstract][Full Text] [Related]
8. BRAF alterations are associated with complex mutational profiles in malignant melanoma.
Daniotti M; Oggionni M; Ranzani T; Vallacchi V; Campi V; Di Stasi D; Torre GD; Perrone F; Luoni C; Suardi S; Frattini M; Pilotti S; Anichini A; Tragni G; Parmiani G; Pierotti MA; Rodolfo M
Oncogene; 2004 Aug; 23(35):5968-77. PubMed ID: 15195137
[TBL] [Abstract][Full Text] [Related]
9. The genetics of cutaneous melanoma.
Pollock PM; Trent JM
Clin Lab Med; 2000 Dec; 20(4):667-90. PubMed ID: 11221509
[TBL] [Abstract][Full Text] [Related]
10. Genetic progression of metastatic melanoma.
Rodolfo M; Daniotti M; Vallacchi V
Cancer Lett; 2004 Oct; 214(2):133-47. PubMed ID: 15363539
[TBL] [Abstract][Full Text] [Related]
11. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.
Gallagher SJ; Thompson JF; Indsto J; Scurr LL; Lett M; Gao BF; Dunleavey R; Mann GJ; Kefford RF; Rizos H
Neoplasia; 2008 Nov; 10(11):1231-9. PubMed ID: 18953432
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
Soufir N; Avril MF; Chompret A; Demenais F; Bombled J; Spatz A; Stoppa-Lyonnet D; Bénard J; Bressac-de Paillerets B
Hum Mol Genet; 1998 Feb; 7(2):209-16. PubMed ID: 9425228
[TBL] [Abstract][Full Text] [Related]
15. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
[TBL] [Abstract][Full Text] [Related]
16. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
17. Melanoma genetics: an update on risk-associated genes.
Udayakumar D; Tsao H
Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594
[TBL] [Abstract][Full Text] [Related]
18. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
19. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
20. Genetics in melanoma.
Stahl S; Bar-Meir E; Friedman E; Regev E; Orenstein A; Winkler E
Isr Med Assoc J; 2004 Dec; 6(12):774-7. PubMed ID: 15609895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
